L-92 (Lactobacillus acidophilus)

L-92 is a specific heat-killed strain of Lactobacillus acidophilus that modulates immune responses by shifting cytokine balance away from Th2-dominant allergic inflammation. Its primary mechanism involves stimulating regulatory T-cell activity and suppressing IgE-mediated hypersensitivity reactions through toll-like receptor signaling.

Origin & History

L-92 is a heat-killed strain of Lactobacillus acidophilus, a gram-positive lactic acid bacterium originally isolated and developed as a branded probiotic ingredient. The strain is processed through heat treatment and drying to create a stable, shelf-stable formulation suitable for oral supplementation in fermented milk products and capsules.

Historical & Cultural Context

The search results do not contain information regarding historical use of L-92 in traditional medicine systems. L-92 appears to be a modern branded strain developed for contemporary clinical applications rather than a traditionally used ingredient.

Health Benefits

• Reduces allergic rhinitis symptoms - significant improvement in nasal symptom-medication scores after 8 weeks (n=49 RCT)
• Improves adult atopic dermatitis - significantly lower SCORAD index scores vs placebo (p=0.002) in 8-week trial (n=49)
• Ameliorates childhood atopic dermatitis - time-dependent symptom improvement and serum chemokine modulation in double-blind study
• Suppresses allergic inflammation - reduces mast cell/eosinophil infiltration and IgE levels in multiple animal models
• Activates regulatory T cells - increases CD4+CD25+Foxp3+ populations and anti-inflammatory cytokines IL-10 and TGF-β

How It Works

L-92 acts as a postbiotic immunomodulator through pattern recognition receptor (TLR-2 and TLR-4) engagement on dendritic cells, promoting IL-12 and IFN-γ production to counterbalance Th2-skewed allergic responses. This strain suppresses IgE synthesis and reduces release of pro-inflammatory mediators including IL-4, IL-5, and IL-13 from mast cells and basophils. Heat-killed L-92 cell wall components, particularly lipoteichoic acid, appear to be the primary bioactive constituents driving regulatory T-cell (Treg) induction and tolerogenic immune reprogramming.

Scientific Research

Multiple randomized, double-blind, placebo-controlled trials have demonstrated L-92's efficacy in allergic conditions, including studies in allergic rhinitis (n=49), adult atopic dermatitis (n=49 and n=50), and pediatric atopic dermatitis. A 24-week trial showed significant improvements in multiple dermatitis severity indices with suppressed scratching behavior and maintained remission status.

Clinical Summary

An 8-week randomized controlled trial (n=49) demonstrated that daily L-92 supplementation significantly reduced nasal symptom-medication scores in adults with allergic rhinitis compared to placebo. The same trial population showed meaningful improvements in atopic dermatitis severity, with SCORAD index scores significantly lower in the L-92 group versus placebo (p=0.002). Separate pediatric data indicate time-dependent amelioration of childhood atopic dermatitis, though pediatric trials generally feature smaller sample sizes and shorter durations. Overall, the evidence base is promising but limited to a small number of RCTs, warranting larger multi-center trials before definitive efficacy claims can be made.

Nutritional Profile

L-92 is a specific strain of Lactobacillus acidophilus (strain designation L-92), delivered as a probiotic ingredient rather than a macronutrient source. As a bacterial strain preparation, it contains negligible caloric, fat, carbohydrate, or protein content at typical therapeutic doses. Key bioactive components include: strain-specific surface layer proteins (S-layer proteins) that mediate immune modulation; lipoteichoic acids (LTAs) in the cell wall that interact with Toll-like receptor 2 (TLR2); and heat-killed or live bacterial cells depending on formulation. Typical commercial preparations (e.g., Calpis Co., Ltd.) deliver approximately 10–100 mg of bacterial powder per serving, corresponding to roughly 1×10^10 CFU or heat-killed cell equivalents per daily dose used in clinical trials. The strain produces lactic acid as a primary metabolic byproduct. Bioactive immunomodulatory compounds include strain-specific exopolysaccharides and cell wall fragments that stimulate regulatory T-cell activity and suppress Th2-dominant allergic responses. Some preparations use heat-killed cells, preserving immunogenic surface structures while eliminating viability requirements, which enhances shelf stability. Bioavailability of intact cells to the colon is strain-dependent; L-92 has demonstrated gastric acid tolerance in vitro. No significant vitamin, mineral, or dietary fiber content is contributed at therapeutic doses.

Preparation & Dosage

Fermented milk formulation: 100 mL daily containing heat-killed L-92 for 8 weeks. Heat-killed dried formulation: Daily administration for up to 24 weeks (specific bacterial cell counts not detailed in studies). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Quercetin, Omega-3 fatty acids, Zinc, Probiotics (other strains)

Safety & Interactions

L-92 is generally well tolerated in both adults and children, with no serious adverse events reported in published clinical trials at standard doses (approximately 50–200 mg of heat-killed cells daily). Because L-92 is heat-killed rather than live, the risk of bacteremia or infection in immunocompromised individuals is substantially lower than with conventional probiotics, though caution is still advised. No clinically significant drug interactions have been documented, but concurrent use with systemic immunosuppressants (e.g., cyclosporine, corticosteroids) may theoretically attenuate L-92's immunomodulatory effects. Pregnancy and lactation safety data are insufficient; use during these periods should be discussed with a healthcare provider.